Journal of Neural Transmission

, Volume 114, Issue 5, pp 621–628

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

  • M. Bibl
  • B. Mollenhauer
  • S. Wolf
  • H. Esselmann
  • P. Lewczuk
  • J. Kornhuber
  • J. Wiltfang
Article

DOI: 10.1007/s00702-006-0618-z

Cite this article as:
Bibl, M., Mollenhauer, B., Wolf, S. et al. J Neural Transm (2007) 114: 621. doi:10.1007/s00702-006-0618-z

Summary.

Cerebrospinal fluid (CSF) carboxyterminally truncated amyloid-beta (Aβ) peptides, Aβ1-42 and tau protein were evaluated in 30 patients with frontotemporal lobe degenerations (FTLD), 30 Alzheimer’s disease (AD) patients and 30 non-demented disease controls (NDC) by Aβ-SDS-PAGE/immunoblot as well as commercial ELISAs for Aβ1-42 and total tau. FTLD displayed a significant drop of Aβ1-37 (p = 2.7 × 10−4), Aβ1-38 (p = 4.2 × 10−5) and Aβ1-42 (p = 3.3 × 10−4). Aβ1-42 was selectively decreased in AD (p = 8.5 × 10−10). Decreased Aβ1-38 enabled contrasts of beyond 85% to distinguish FTLD from AD and NDC patients, alone or in combination. Accordingly, low CSF Aβ1-37 and Aβ1-38 represent a biomarker candidate for FTLD and may reflect disease-specific changes of APP metabolism. Further validation should be carried out on dementias other than AD, diagnostically relevant control groups without dementia and without any evident affection of the central nervous system and subgroups of FTLD. Moreover, independent methods of measurement should be applied to CSF Aβ1-38.

Keywords: Alzheimer’s disease, frontotemporal degeneration, cerebrospinal fluid, amyloid-β peptides, biomarkers

Abbreviations:

Aβ peptides

Amyloid-beta peptides

Aβ-SDS-PAGE/immunoblot

amyloid-beta-sodium-dodecyl-sulphate-polyacrylamide-gel-electrophoresis with western immunoblot

AD

Alzheimer’s disease

APP

beta-amyloid precursor protein

bicine

N,N′-bis-[2-hydroxyethyl]glycine

%C

percentage of N,N′-bis-acrylamide

CCD-camera

charge coupled device camera

CSF

cerebrospinal fluid

Ct-elongated

carboxyterminally elongated

Ct-truncated

carboxyterminally truncated

ECL

enhanced chemiluminescence

ELISA

Enzyme Linked Immunosorbent Assay

FTLD

frontotemporal lobe degenerations

MMSE

Mini-Mental-Status Examination

NDC

non-demented disease controls

NINCDS-ADRDA

National Institute Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association

SDS

sodium dodecyl sulphate

%T

percentage of acrylamide

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Bibl
    • 1
  • B. Mollenhauer
    • 2
  • S. Wolf
    • 2
  • H. Esselmann
    • 3
  • P. Lewczuk
    • 3
  • J. Kornhuber
    • 3
  • J. Wiltfang
    • 3
  1. 1.Department of PsychiatryUniversity of GoettingenGoettingenGermany
  2. 2.Brigham and Women’s Hospital, Center for Neurologic DiseasesHarvard Medical SchoolBostonUSA
  3. 3.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany